{
    "hands_on_practices": [
        {
            "introduction": "Effective management of pheochromocytoma begins with accurate diagnosis, but interpreting screening tests for a rare condition presents unique statistical challenges. A test's performance is not just about its sensitivity and specificity, but also about its predictive value in a given population. This first exercise  provides a quantitative foundation for understanding why a positive screening result for pheochromocytoma must be approached with caution and necessitates a structured confirmatory process.",
            "id": "5170906",
            "problem": "A tertiary referral center is evaluating patients with suspected catecholamine-secreting chromaffin tumors consistent with pheochromocytoma. Plasma free metanephrines are obtained as part of biochemical screening. In the referred population, the disease prevalence is $0.5\\%$, the test sensitivity is $97\\%$, and the test specificity is $90\\%$. Using only the definitions of sensitivity, specificity, and prevalence together with Bayes’ theorem, derive the expression for the Positive Predictive Value (PPV) defined as $P(\\text{Disease} \\mid \\text{Test positive})$, then compute its numerical value for this population. Finally, based on your computed $PPV$, state whether confirmatory testing should be pursued before surgical planning for resection and preoperative optimization with alpha-adrenergic blockade. Round your final numerical answer to four significant figures and express it as a decimal without a percent sign.",
            "solution": "The problem is valid as it is scientifically grounded, well-posed, and objective. It provides all necessary information to derive and compute the Positive Predictive Value (PPV) for a diagnostic test in a specified clinical context.\n\nLet $D$ be the event that a patient has the disease (pheochromocytoma), and let $T^+$ be the event that the biochemical screening test is positive. The prevalence of the disease is given as $P(D) = 0.5\\% = 0.005$. The sensitivity of the test is the probability of a positive test given the patient has the disease, which is $P(T^+ \\mid D) = 97\\% = 0.97$. The specificity of the test is the probability of a negative test given the patient does not have the disease. Let $D^c$ be the event that a patient does not have the disease. Then the specificity is $P(T^- \\mid D^c) = 90\\% = 0.90$.\n\nThe quantity to be calculated is the Positive Predictive Value (PPV), defined in the problem as $P(D \\mid T^+)$. This is the probability that a patient has the disease given that they have a positive test result.\n\nUsing the definition of conditional probability, also known as Bayes' theorem, we can express the PPV as:\n$$P(D \\mid T^+) = \\frac{P(T^+ \\mid D) P(D)}{P(T^+)}$$\n\nThe denominator, $P(T^+)$, represents the total probability of obtaining a positive test result in the given population. This can be calculated using the law of total probability, which sums the probabilities of a positive test over all possible disease states (having the disease or not having the disease):\n$$P(T^+) = P(T^+ \\mid D) P(D) + P(T^+ \\mid D^c) P(D^c)$$\n\nTo evaluate this expression, we need the values for all terms. We are given:\n- Prevalence: $P(D) = 0.005$.\n- Sensitivity: $P(T^+ \\mid D) = 0.97$.\n\nFrom these, we can derive the remaining probabilities:\n- The probability of not having the disease is $P(D^c) = 1 - P(D) = 1 - 0.005 = 0.995$.\n- The probability of a positive test in a patient without the disease, $P(T^+ \\mid D^c)$, is the complement of the specificity. Since for a given state $D^c$, the test can only be positive ($T^+$) or negative ($T^-$), the sum of their probabilities is $1$. Thus, $P(T^+ \\mid D^c) = 1 - P(T^- \\mid D^c)$. This term is also known as the false positive rate.\n$$P(T^+ \\mid D^c) = 1 - \\text{specificity} = 1 - 0.90 = 0.10$$\n\nSubstituting the expression for $P(T^+)$ into the formula for PPV, we obtain the general expression for PPV in terms of prevalence, sensitivity, and specificity:\n$$PPV = P(D \\mid T^+) = \\frac{P(T^+ \\mid D) P(D)}{P(T^+ \\mid D) P(D) + P(T^+ \\mid D^c) P(D^c)}$$\n\nNow, we substitute the numerical values into this derived expression:\n$$PPV = \\frac{(0.97) \\times (0.005)}{(0.97) \\times (0.005) + (0.10) \\times (0.995)}$$\n\nFirst, we compute the numerator:\n$$\\text{Numerator} = 0.97 \\times 0.005 = 0.00485$$\n\nNext, we compute the denominator:\n$$\\text{Denominator} = (0.97 \\times 0.005) + (0.10 \\times 0.995) = 0.00485 + 0.0995 = 0.10435$$\n\nFinally, we compute the PPV:\n$$PPV = \\frac{0.00485}{0.10435} \\approx 0.0464829904168663...$$\n\nRounding the numerical value to four significant figures as requested, we get:\n$$PPV \\approx 0.04648$$\n\nThis result means that in this population of patients referred for suspected pheochromocytoma, a positive plasma free metanephrine test indicates only a $4.648\\%$ probability that the patient actually has the disease. Conversely, the probability that a positive result is a false positive is $1 - 0.04648 = 0.95352$, or approximately $95.4\\%$.\n\nGiven the low Positive Predictive Value, a positive screening test is not sufficient to confirm the diagnosis of pheochromocytoma. Proceeding directly to surgical planning and preoperative optimization with alpha-adrenergic blockade based on this single test would be inappropriate. The risks and morbidity associated with pheochromocytoma resection are substantial, and such interventions require a high degree of diagnostic certainty. Therefore, based on the computed PPV, confirmatory testing is absolutely mandatory. This would typically involve subsequent investigations, such as 24-hour urinary fractionated metanephrines and catecholamines, and/or imaging studies like CT or MRI to anatomically localize a potential tumor, before any surgical intervention is considered.",
            "answer": "$$\\boxed{0.04648}$$"
        },
        {
            "introduction": "Following an initial suspicious result, the diagnostic pathway often involves navigating borderline biochemical elevations confounded by physiologic stress or medications. A robust, stepwise algorithm is essential to increase diagnostic certainty before committing a patient to imaging or surgery. This practice  challenges you to construct such an algorithm, integrating a key pharmacologic tool—the clonidine suppression test—with subsequent imaging decisions to logically resolve diagnostic ambiguity.",
            "id": "5170970",
            "problem": "A $45$-year-old with paroxysmal hypertension, headaches, and diaphoresis is referred for evaluation of possible pheochromocytoma. Initial outpatient plasma testing (seated, no medication washout) showed plasma free normetanephrine at $1.7 \\times$ the upper limit of normal (ULN) with normal plasma metanephrine. After a $14$-day washout of tricyclic antidepressants and serotonin–norepinephrine reuptake inhibitors and after $30$ minutes of supine rest, repeat plasma sampling shows isolated plasma free normetanephrine at $1.4 \\times$ ULN, plasma metanephrine normal, and $24$-hour urinary fractionated metanephrines within reference range. There is no chronic kidney disease and no known germline mutation. Based on symptoms and the borderline biochemical profile, you estimate the pretest probability of pheochromocytoma at approximately $15\\%$.\n\nYou plan a clonidine suppression test because the elevation is borderline and confined to normetanephrine. For the purpose of decision-making, assume the following are well-tested performance characteristics of the clonidine suppression test when interpreted for plasma normetanephrine in this context: sensitivity approximately $95\\%$, specificity approximately $95\\%$, using a criterion of a decrease in plasma normetanephrine of at least $40\\%$ from baseline and/or suppression to below ULN at $3$ hours to define a negative test.\n\nYour task is to choose the decision tree that correctly integrates these prior results with the possible clonidine suppression outcomes to determine whether functional imaging is indicated. Functional imaging includes agents such as iodine-$123$ metaiodobenzylguanidine ($^{123}$I-MIBG), Gallium-$68$ DOTATATE ($^{68}$Ga-DOTATATE), or Fluorine-$18$ fluorodeoxyglucose ($^{18}$F-FDG).\n\nWhich of the following decision trees is most appropriate?\n\nA. After medication washout and supine sampling confirm isolated borderline plasma free normetanephrine $<2 \\times$ ULN with normal metanephrine and urine, perform clonidine suppression. If plasma normetanephrine suppresses by $\\ge 40\\%$ and/or to below ULN at $3$ hours, do not pursue imaging and reassess clinically. If it fails to suppress, proceed to contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) for anatomic localization. Reserve functional imaging for cases with negative or indeterminate CT/MRI, suspected extra-adrenal or metastatic disease, or known high-risk genotype (for example, succinate dehydrogenase complex iron sulfur subunit B, SDHB).\n\nB. Any borderline elevation of plasma free normetanephrine after medication washout warrants immediate functional imaging with $^{123}$I-MIBG; clonidine suppression is unnecessary because a positive biochemical result already justifies imaging.\n\nC. Perform clonidine suppression; because the test cannot safely exclude disease in borderline cases, obtain functional imaging regardless of whether normetanephrine suppresses, to avoid missing small or extra-adrenal tumors.\n\nD. Perform clonidine suppression. If normetanephrine suppresses by $\\ge 40\\%$ and/or to below ULN at $3$ hours, proceed to CT or MRI to be safe; if it fails to suppress, bypass anatomic imaging and proceed directly to functional imaging to capitalize on higher specificity.\n\nE. Clonidine suppression should be reserved for elevated plasma metanephrine; for isolated normetanephrine elevations, skip clonidine and proceed to functional imaging because clonidine does not inform norepinephrine-driven physiology.",
            "solution": "The clinical base includes the physiology of catecholamine production and metabolism, the concept that clonidine (an alpha-$2$ adrenergic agonist) suppresses sympathetic neural outflow and thereby lowers norepinephrine and its metabolite normetanephrine in non-tumor states, but does not suppress autonomous catecholamine secretion from a pheochromocytoma. In patients with borderline, isolated plasma free normetanephrine elevation, the clonidine suppression test has high specificity and sensitivity when interpreted using a stringent criterion (for example, a $\\ge 40\\%$ fall and/or suppression to below the upper limit of normal at $3$ hours). A decision should be grounded in Bayesian updating of disease probability and in standard imaging algorithms for pheochromocytoma.\n\nStart from Bayes’ theorem in odds form. Let the pretest probability be $P_{0} = 0.15$. Then the pretest odds are\n$$\n\\text{Odds}_{0} = \\frac{P_{0}}{1 - P_{0}} = \\frac{0.15}{0.85} \\approx 0.17647.\n$$\nFor a positive clonidine test (failure to suppress), with sensitivity $S = 0.95$ and specificity $C = 0.95$, the positive likelihood ratio is\n$$\n\\text{LR}_{+} = \\frac{S}{1 - C} = \\frac{0.95}{1 - 0.95} = \\frac{0.95}{0.05} = 19.\n$$\nThe posterior odds after a positive result are\n$$\n\\text{Odds}_{+} = \\text{Odds}_{0} \\times \\text{LR}_{+} \\approx 0.17647 \\times 19 \\approx 3.35293,\n$$\nyielding a posterior probability\n$$\nP_{+} = \\frac{\\text{Odds}_{+}}{1 + \\text{Odds}_{+}} \\approx \\frac{3.35293}{1 + 3.35293} \\approx 0.770 \\,\\, (\\text{or } 77.0\\%).\n$$\nThis level of posterior probability justifies proceeding with localization imaging. Standard practice in pheochromocytoma is to perform contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) first for anatomic localization, then use functional imaging such as iodine-$123$ metaiodobenzylguanidine ($^{123}$I-MIBG), Gallium-$68$ DOTATATE ($^{68}$Ga-DOTATATE), or Fluorine-$18$ fluorodeoxyglucose ($^{18}$F-FDG) when anatomic imaging is negative or indeterminate, when extra-adrenal or metastatic disease is suspected, or when high-risk genotypes (for example, succinate dehydrogenase complex iron sulfur subunit B, SDHB) are present.\n\nFor a negative clonidine result (adequate suppression), the negative likelihood ratio is\n$$\n\\text{LR}_{-} = \\frac{1 - S}{C} = \\frac{1 - 0.95}{0.95} = \\frac{0.05}{0.95} \\approx 0.05263.\n$$\nThe posterior odds after a negative result are\n$$\n\\text{Odds}_{-} = \\text{Odds}_{0} \\times \\text{LR}_{-} \\approx 0.17647 \\times 0.05263 \\approx 0.00928,\n$$\nand the posterior probability is\n$$\nP_{-} = \\frac{\\text{Odds}_{-}}{1 + \\text{Odds}_{-}} \\approx \\frac{0.00928}{1 + 0.00928} \\approx 0.00919 \\,\\, (\\text{or } 0.92\\%).\n$$\nA posterior probability under approximately $1\\%$ falls below a practical action threshold for imaging, especially functional imaging, given radiation exposure and low diagnostic yield. In such a case, the correct course is to avoid imaging and to reassess clinically, possibly repeating biochemistry if symptoms evolve.\n\nFinally, test selection nuances matter: clonidine suppression is specifically informative for elevations of plasma norepinephrine or normetanephrine; it is not appropriate for isolated plasma metanephrine elevations where epinephrine-driven secretion from adrenal chromaffin cells predominates, because clonidine’s central sympatholytic effect will not necessarily influence autonomous epinephrine production.\n\nOption-by-option analysis:\n\nA. This algorithm respects preanalytic correction, applies clonidine suppression appropriately to isolated borderline plasma free normetanephrine, interprets suppression using a stringent criterion, uses Bayesian reasoning implicitly to avoid imaging when posterior probability becomes very low (as shown by $P_{-} \\approx 0.92\\%$), and follows standard sequencing of imaging by performing CT or MRI first after a positive biochemical confirmation, reserving functional imaging for negative or indeterminate anatomic imaging, suspected extra-adrenal or metastatic disease, or high-risk genotypes (for example, SDHB). This aligns with endocrine and surgical best practice. Correct.\n\nB. This disregards the low positive predictive value of borderline elevations even after washout and discards the discriminative value of clonidine suppression. It inappropriately elevates any borderline abnormality to warrant immediate functional imaging, which is neither efficient nor standard. Incorrect.\n\nC. This assumes clonidine suppression cannot reduce disease probability sufficiently in borderline cases. However, with $S \\approx 95\\%$ and $C \\approx 95\\%$, a negative test reduces the posterior to approximately $0.92\\%$, which does not justify functional imaging. Incorrect.\n\nD. This reverses the imaging sequence by sending positive clonidine cases straight to functional imaging and needlessly imaging negative clonidine cases with CT or MRI. Standard practice is to forgo imaging when posterior probability is very low, and when imaging is indicated after a positive biochemical test, to begin with anatomic localization (CT or MRI) and reserve functional imaging for specific indications. Incorrect.\n\nE. This misstates the role of clonidine suppression. The test is validated for norepinephrine/normetanephrine physiology and is most useful for isolated normetanephrine elevations; it is not recommended for isolated metanephrine elevations. Skipping clonidine and going straight to functional imaging in isolated normetanephrine cases is contrary to evidence and practice. Incorrect.\n\nTherefore, the decision tree in option A is the most appropriate.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Once pheochromocytoma is biochemically confirmed, meticulous preoperative preparation is paramount to ensure a safe resection by controlling blood pressure and restoring intravascular volume. The cornerstone of this optimization is alpha-adrenergic blockade, which requires careful titration to achieve therapeutic goals without causing excessive hypotension. This final practice  simulates the real-world task of designing and executing a phenoxybenzamine titration schedule based on patient-specific data and clinical endpoints.",
            "id": "5170918",
            "problem": "A patient with biochemically confirmed pheochromocytoma is scheduled for adrenalectomy in $12$ days. Preoperative alpha-adrenergic blockade with phenoxybenzamine is planned. The fundamental hemodynamic relationship is $$MAP = CO \\times SVR,$$ where Mean Arterial Pressure (MAP) depends on Cardiac Output (CO) and Systemic Vascular Resistance (SVR). Catecholamine excess increases $SVR$, raising $MAP$. Alpha-adrenergic blockade reduces $SVR$, thereby lowering $MAP$ and blunting reflex vasoconstriction on standing. Orthostatic hypotension is defined by a fall in systolic Blood Pressure (BP) of $\\geq 20$ mmHg and/or diastolic BP of $\\geq 10$ mmHg within $3$ minutes of standing; mild orthostasis and nasal congestion are pragmatic clinical markers of adequate alpha blockade because alpha-adrenergic tone supports venous return on standing and nasal mucosal vasoconstriction at rest. \n\nYou will initiate phenoxybenzamine at $10$ mg twice daily ($20$ mg/day). Dose increases of $10$–$20$ mg/day may be made no more frequently than every $2$–$3$ days, and the patient can attend clinic on days $3$, $6$, and $9$ for dose reassessment. Because phenoxybenzamine produces irreversible receptor blockade with downstream physiologic equilibration requiring volume repletion, hemodynamic evaluation should occur after at least $48$–$72$ hours at a stable dose to ensure steady effect.\n\nEmpiric dose-response data for this patient, measured after stabilization at each dose, are as follows:\n- At $20$ mg/day: supine BP $150/95$ mmHg, standing BP $140/90$ mmHg, nasal congestion absent.\n- At $40$ mg/day: supine BP $140/92$ mmHg, standing BP $120/86$ mmHg, nasal congestion minimal.\n- At $50$ mg/day: supine BP $130/88$ mmHg, standing BP $105/80$ mmHg, nasal congestion present.\n- At $60$ mg/day: supine BP $118/82$ mmHg, standing BP $85/70$ mmHg, nasal congestion significant.\n\nThe target for adequate preoperative alpha blockade is defined for this problem as mild orthostasis with standing systolic BP between $90$ and $110$ mmHg, an orthostatic systolic drop of $\\geq 20$ mmHg, and nasal congestion present, without symptoms of severe hypotension. \n\nWhich titration schedule best satisfies the dosing constraints, uses clinic reassessment days of $3$, $6$, and $9$, respects the $48$–$72$ hour stabilization requirement before deciding on adequacy, and achieves the target as early as possible without overshooting?\n\nA. Day $0$: $20$ mg/day. Day $2$: increase to $40$ mg/day. Day $4$: increase to $60$ mg/day. Declare target achieved on day $4$ and maintain $60$ mg/day to surgery.\n\nB. Day $0$: $20$ mg/day. Day $3$: increase to $40$ mg/day. Day $6$: increase to $50$ mg/day. Day $8$: evaluate after $48$ hours at $50$ mg/day; target achieved; maintain $50$ mg/day to surgery.\n\nC. Day $0$: $20$ mg/day. Day $3$: increase to $30$ mg/day. Day $6$: increase to $40$ mg/day. Day $9$: increase to $50$ mg/day. Day $11$: evaluate after $48$ hours at $50$ mg/day; target achieved; maintain $50$ mg/day to surgery.\n\nD. Day $0$: $20$ mg/day. Day $3$: increase to $40$ mg/day. Day $6$: increase to $60$ mg/day. Day $9$: evaluate after $72$ hours at $60$ mg/day; target achieved; maintain $60$ mg/day to surgery.\n\nE. Day $0$: $20$ mg/day. Day $3$: increase to $30$ mg/day. Day $6$: increase to $50$ mg/day. Declare target achieved on day $6$ and maintain $50$ mg/day to surgery.",
            "solution": "### Problem Validation\n\nThis is a clinical optimization problem grounded in pharmacology and physiology. The validation will proceed by first extracting the givens and then evaluating them against the criteria of scientific soundness, objectivity, and completeness.\n\n#### Step 1: Extract Givens\n\n1.  **Scheduled Procedure:** Adrenalectomy in $12$ days for biochemically confirmed pheochromocytoma.\n2.  **Preoperative Medication:** Phenoxybenzamine for alpha-adrenergic blockade.\n3.  **Fundamental Physiology:** $MAP = CO \\times SVR$. Catecholamine excess increases $SVR$ and $MAP$. Alpha-blockade reduces $SVR$ and $MAP$.\n4.  **Clinical Signs of Blockade:** Orthostatic hypotension and nasal congestion.\n5.  **Definition of Orthostatic Hypotension:** Fall in systolic BP $\\geq 20$ mmHg and/or diastolic BP $\\geq 10$ mmHg within $3$ minutes of standing.\n6.  **Titration Protocol:**\n    *   **Starting Dose:** $10$ mg twice daily ($20$ mg/day), initiated on Day $0$.\n    *   **Dose Increases:** Increments of $10$–$20$ mg/day.\n    *   **Frequency of Increase:** No more frequently than every $2$–$3$ days.\n    *   **Reassessment Schedule:** Clinic visits on Day $3$, Day $6$, and Day $9$. Dose adjustments occur on these days.\n    *   **Stabilization Period:** Hemodynamic evaluation must occur after at least $48$–$72$ hours at a stable dose.\n7.  **Empiric Dose-Response Data:**\n    *   $20$ mg/day: Supine BP $150/95$ mmHg, Standing BP $140/90$ mmHg.\n    *   $40$ mg/day: Supine BP $140/92$ mmHg, Standing BP $120/86$ mmHg.\n    *   $50$ mg/day: Supine BP $130/88$ mmHg, Standing BP $105/80$ mmHg.\n    *   $60$ mg/day: Supine BP $118/82$ mmHg, Standing BP $85/70$ mmHg.\n8.  **Target for Adequate Blockade:**\n    *   Standing systolic BP between $90$ mmHg and $110$ mmHg.\n    *   Orthostatic systolic drop $\\geq 20$ mmHg.\n    *   Nasal congestion present.\n    *   Absence of symptoms of severe hypotension.\n9.  **Optimization Goal:** Find the titration schedule that satisfies all constraints, uses the specified clinic days, respects stabilization time, and achieves the target as early as possible without overshooting.\n\n#### Step 2: Validate Using Extracted Givens\n\n*   **Scientifically Grounded:** The problem is firmly based on established principles of cardiovascular physiology ($MAP = CO \\times SVR$) and pharmacology (the mechanism of action and clinical effects of phenoxybenzamine in managing pheochromocytoma). The definitions and values provided are medically and scientifically accurate.\n*   **Well-Posed:** The problem provides a clear set of initial conditions, constraints, empirical data, and a well-defined target. The objective function (achieve target \"as early as possible\") makes it an optimization problem for which a unique best solution among the options can be identified.\n*   **Objective:** The problem uses precise, quantitative definitions for orthostasis and the therapeutic target. The dose-response data is provided as an empirical fact for this specific case. The language is objective and free of subjective claims.\n\nThe problem statement is internally consistent, scientifically sound, and well-posed. There are no violations of the validation criteria.\n\n#### Step 3: Verdict and Action\n\nThe problem statement is **valid**. Proceeding to the solution.\n\n### Solution Derivation\n\nThe goal is to find the optimal titration schedule to achieve a specific hemodynamic state. First, we must identify which dose level meets the target criteria.\n\n**Analysis of Dose-Response Data:**\nThe target is defined by three conditions:\n1.  Standing Systolic BP (SBP): $90 \\leq \\text{SBP}_{\\text{standing}} \\leq 110$ mmHg.\n2.  Orthostatic Systolic Drop: $\\text{SBP}_{\\text{supine}} - \\text{SBP}_{\\text{standing}} \\geq 20$ mmHg.\n3.  Side Effect: Nasal congestion must be \"present\".\n\nLet's evaluate each dose from the provided data:\n*   **$20$ mg/day:**\n    *   Standing SBP = $140$ mmHg (outside $[90, 110]$).\n    *   Systolic drop = $150 - 140 = 10$ mmHg ($< 20$ mmHg).\n    *   Nasal congestion: absent.\n    *   **Conclusion: Target not met.**\n*   **$40$ mg/day:**\n    *   Standing SBP = $120$ mmHg (outside $[90, 110]$).\n    *   Systolic drop = $140 - 120 = 20$ mmHg ($\\geq 20$ mmHg).\n    *   Nasal congestion: minimal (may not satisfy \"present\").\n    *   **Conclusion: Target not met.**\n*   **$50$ mg/day:**\n    *   Standing SBP = $105$ mmHg (within $[90, 110]$).\n    *   Systolic drop = $130 - 105 = 25$ mmHg ($\\geq 20$ mmHg).\n    *   Nasal congestion: present.\n    *   **Conclusion: Target is met.**\n*   **$60$ mg/day:**\n    *   Standing SBP = $85$ mmHg (outside $[90, 110]$; this is an overshoot).\n    *   Systolic drop = $118 - 85 = 33$ mmHg ($\\geq 20$ mmHg).\n    *   Nasal congestion: significant.\n    *   **Conclusion: Target is overshot.**\n\nThe optimal dose is therefore $50$ mg/day. The problem reduces to finding the fastest valid schedule to reach and confirm stabilization at $50$ mg/day.\n\n**Analysis of Titration Schedules:**\nConstraints to check for each option:\n*   Titration occurs only on clinic days (Day $3$, $6$, $9$).\n*   Dose increments are between $10$ mg/day and $20$ mg/day.\n*   Dose changes are at least $2$–$3$ days apart (guaranteed by clinic schedule).\n*   Evaluation of target achievement occurs only after $48$–$72$ hours on the final dose.\n*   The final dose must be the target dose ($50$ mg/day).\n\n### Option-by-Option Analysis\n\n**A. Day $0$: $20$ mg/day. Day $2$: increase to $40$ mg/day. Day $4$: increase to $60$ mg/day. Declare target achieved on day $4$ and maintain $60$ mg/day to surgery.**\n*   This schedule violates the constraint that dose reassessment and changes occur on clinic days ($3$, $6$, $9$). Changes are made on days $2$ and $4$.\n*   It incorrectly selects a dose of $60$ mg/day, which overshoots the target.\n*   It violates the stabilization rule by declaring the target achieved on Day $4$, the same day the dose was increased. An evaluation requires waiting at least $48$ hours.\n*   **Verdict: Incorrect.**\n\n**B. Day $0$: $20$ mg/day. Day $3$: increase to $40$ mg/day. Day $6$: increase to $50$ mg/day. Day $8$: evaluate after $48$ hours at $50$ mg/day; target achieved; maintain $50$ mg/day to surgery.**\n*   **Day $0$: Start $20$ mg/day.** Correct.\n*   **Day $3$: Increase to $40$ mg/day.** This is a clinic day. The increase is $20$ mg/day, which is within the allowed range [$10, 20$]. The interval is $3$ days. All rules are satisfied.\n*   **Day $6$: Increase to $50$ mg/day.** This is a clinic day. The increase is $10$ mg/day, which is within the allowed range. The interval is $3$ days. All rules are satisfied. The patient is now on the target dose.\n*   **Day $8$: Evaluate.** Day $8$ is $48$ hours after the dose change on Day $6$. This respects the $48$–$72$ hour stabilization requirement. At $50$ mg/day, the target is achieved. This schedule reaches the target and confirms it at the earliest possible time given the constraints.\n*   **Verdict: Correct.**\n\n**C. Day $0$: $20$ mg/day. Day $3$: increase to $30$ mg/day. Day $6$: increase to $40$ mg/day. Day $9$: increase to $50$ mg/day. Day $11$: evaluate after $48$ hours at $50$ mg/day; target achieved; maintain $50$ mg/day to surgery.**\n*   This schedule follows all rules regarding clinic days, dose increments, and stabilization time.\n*   However, it employs a less aggressive titration. The target dose of $50$ mg/day is not started until Day $9$, with confirmation on Day $11$.\n*   Schedule B starts the target dose on Day $6$ with confirmation on Day $8$.\n*   Since the goal is to achieve the target \"as early as possible,\" this schedule is suboptimal compared to schedule B.\n*   **Verdict: Incorrect.**\n\n**D. Day $0$: $20$ mg/day. Day $3$: increase to $40$ mg/day. Day $6$: increase to $60$ mg/day. Day $9$: evaluate after $72$ hours at $60$ mg/day; target achieved; maintain $60$ mg/day to surgery.**\n*   The titration schedule itself is valid up to the dose selection.\n*   The fatal flaw is the choice of the final dose. On Day $6$, the dose is increased to $60$ mg/day. As determined from the data, this dose overshoots the target, with standing systolic BP falling to $85$ mmHg. The statement \"target achieved\" is false.\n*   **Verdict: Incorrect.**\n\n**E. Day $0$: $20$ mg/day. Day $3$: increase to $30$ mg/day. Day $6$: increase to $50$ mg/day. Declare target achieved on day $6$ and maintain $50$ mg/day to surgery.**\n*   The titration schedule (dose increases on clinic days) is valid.\n*   The fatal flaw is the evaluation timing. It declares the target achieved on Day $6$, the same day the dose was increased to $50$ mg/day. This violates the mandatory $48$–$72$ hour stabilization period before evaluation.\n*   **Verdict: Incorrect.**",
            "answer": "$$\\boxed{B}$$"
        }
    ]
}